Vinay Prasad MD MPH is a hematologist-oncologist and Professor in the Department of Epidemiology and Biostatistics at the University of California San Francisco. He runs the VKPrasad lab at UCSF, which studies cancer drugs, health policy, clinical trials and better decision making.

He is author of over 500 academic articles, and the books Ending Medical Reversal, and Malignant. He hosts the oncology podcast Plenary Session, the general medicine podcast the VPZD show, is active on Substack and runs a YouTube Channel VinayPrasadMDMPH. He runs The Drug Development Letter, a must read for industry insights. He tweets @VPrasadMDMPH. op-eds.

A positive look at the FDA appointment of Marty Makary.

As you can see, Dr. Makary is far more qualified for this job than most of his predecessors.

Dr. Martin Makary

From Johns Hopkins Medicine:

Dr. Marty Makary is a surgeon and public policy researcher at Johns Hopkins University. He writes for The Washington Post and The Wall Street Journal and is the author of two New York Times bestselling books, Unaccountable and The Price We Pay. Dr. Makary served in leadership at the World Health Organization Patient Safety Program and has been elected to the National Academy of Medicine.

Clinically, Dr. Makary is the chief of Islet Transplant Surgery at Johns Hopkins. He is the recipient of the Nobility in Science Award from the National Pancreas Foundation and has been a visiting professor at over 25 medical schools. He has published over 250 peer-reviewed scientific articles and has served on several editorial boards.

Dr. Makary is the recipient of the 2020 Business Book of the Year Award by the Association of Business Journalists for his most recent book, The Price We Pay. It has been described by Don Berwick as “a deep dive into the real issues driving up the price of health care” and by Steve Forbes as “A must-read for every American”.

Dr. Makary serves as a professor at the Johns Hopkins School of Medicine and a professor, by courtesy, at the Johns Hopkins Carey Business School. His current research focuses on the underlying causes of disease, public policy, health care costs, and relationship-based medicine.